FDA Orders Nationwide Recall of Xanax XR Over Dissolution Issues

The FDA announced a voluntary recall of a specific Xanax XR lot (3 mg, 60 tablets; lot 8177156; exp 02/28/2027) due to failed dissolution specifications, a Class II recall; risk is considered negligible and no adverse reactions have been reported. The affected tablets were distributed in the U.S. from Aug 27, 2024, to May 29, 2025. If you’re taking Xanax XR, check your bottle’s lot and expiration and contact your doctor or pharmacist if you have concerns; other Xanax XR batches and generics are not affected.